Absolute quantitation of met using mass spectrometry for clinical application: Assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Catenacci, Daniel V T ^a   Liao, Wei Li ^b   Thyparambil, Sheeno ^b   Henderson, Les ^a   Xu, Peng ^a   Zhao, Lei ^a   Rambo, Brittany ^a   Hart, John ^a   Xiao, Shu Yuan ^a   Bengali, Kathleen ^b   Uzzell, Jamar ^b   Darfler, Marlene ^b   Krizman, David B ^b   Cecchi, Fabiola ^c   Bottaro, Donald P ^c   Karrison, Theodore ^a   Veenstra, Timothy D ^b   Hembrough, Todd ^b   Burrows, Jon ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Onco Plex Diagnostics Inc   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN;

ARTICLE; EMBEDDING; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL CANCER; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID TISSUE SELECTED REACTION MONITORING MASS SPECTROMETRY; MASS SPECTROMETRY; MEASUREMENT ACCURACY; MET GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; ESOPHAGUS TUMOR; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; PROCEDURES; STOMACH TUMOR;

ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 84903748385     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100586     Document Type: Article

References (50)

1. Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9: 314-326.
2. Cecchi F, Rabe DC, Bottaro DP (2012) Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 553-572.
3. Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848.
4. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, et al. (2011) RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 12: 9-46.
5. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, et al. (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29: 4789-4795.
6. Liu X, Yao W, Newton RC, Scherle PA (2008) Targeting the Met signaling pathway for cancer therapy. Expert Opin Investig Drugs 17: 997-1011.
7. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, et al. (2012) cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18: 2269-2277.
8. Sadiq AA, Salgia R (2013) MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31: 1089-1096.
9. Sharma N, Adjei AA (2011) In the clinic: ongoing clinical trials evaluating Met-inhibiting drugs. Ther Adv Med Oncol 3: S37-50.
10. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103.
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. (Pubitemid 46799492)
12. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
13. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, et al. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103: 2316-2321.
14. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, et al. (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29: 4803-4810.
15. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, et al. (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47: 1025-1037.
16. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, et al. (2005) The HGF receptor Met is overexpressed in esophageal adenocarcinoma. Neoplasia 7: 75-84. (Pubitemid 40209473)
17. Sehdev A, Catenacci DV (2013) Gastroesophageal cancer: focus on epidemiology, classification, and staging. Discov Med 16: 103-111.
18. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, et al. (2011) Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 1: 573-579.
19. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, et al. (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (Met) protein autophosphorylation by ARQ 197. J Biol Chem 286: 20666-20676.
20. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, et al. (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30.
21. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, et al. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated Met receptor. Cancer Res 70: 1524-1533.
22. Rickert KW, Patel SB, Allison TJ, Byrne NJ, Darke PL, et al. (2011) Structural basis for selective small molecule kinase inhibition of activated Met. J Biol Chem 286: 11218-11225.
23. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, et al. (2013) Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 8: e54014.
24. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the Met signaling pathway in cancer. Clin Cancer Res 15: 2207-2214.
25. Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, et al. (2008) Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 7: 1913-1922.
26. Dai Y, Siemann DW (2010) BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 9: 1554-1561.
27. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, et al. (2007) A selective small molecule inhibitor of Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 67: 3529-3534. (Pubitemid 46762132)
28. Meng Z, Veenstra TD (2011) Targeted mass spectrometry approaches for protein biomarker verification. J Proteomics 74: 2650-2659.
29. Liebler DC, Zimmerman LJ (2013) Targeted quantitation of proteins by mass spectrometry. Biochemistry 52: 3797-3806.
30. Hembrough T, Thyparambil S, Liao WL, Darfler MM, Abdo J, et al. (2013) Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J Mol Diagn 15: 454-465.
31. Hembrough T, Thyparambil S, Liao WL, Darfler MM, Abdo J, et al. (2012) Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue. Clin Proteomics 9: 5.
32. Prioleau J, Schnitt SJ (1995) p53 antigen loss in stored paraffin slides. N Engl J Med 332: 1521-1522.
33. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ (1996) Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88: 1054-1059. (Pubitemid 26260491)
34. Mirlacher M, Kasper M, Storz M, Knecht Y, Durmuller U, et al. (2004) Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 17: 1414-1420. (Pubitemid 39472998)
35. Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, et al. (2009) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10: 365.
36. von Ahlfen S, Missel A, Bendrat K, Schlumpberger M (2007) Determinants of RNA quality from FFPE samples. PLoS One 2: e1261.
37. Sauter G, Simon R, Hillan K (2003) Tissue microarrays in drug discovery. Nat Rev Drug Discov 2: 962-972. (Pubitemid 37540578)
38. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, et al. (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107: 325-333.
39. Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, et al. (2012) Co-expression of hepatocyte growth factor and Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/Met signaling in gastric cancer. Int J Cancer 130: 2912-2921.
40. Zhao J, Zhang X, Xin Y (2011) Up-regulated expression of Ezrin and Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol 26: 1111-1120.
41. Catenacci DVT, Henderson L, Peng Xu, Rambo B, Liao WL, et al. (2014) Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): strategies to address tumor heterogeneity - PANGEA.; Abstr 66, 2014; San Francisco, CA. January 16-18.
42. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, et al. (2013) Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 31: 4445-4452.
43. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, et al. (2013) Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31: 4105-4114.
44. Bart K (2014) Roche halts study on experimental cancer drug MetMab. Zurich. Reuters.
45. Catenacci DVT XP, Henderson L, Liao WL, Burrows J, Hembrough T. (2012) Development of a quantitative gastroesophageal cancer selected reaction monitoring mass spectrometric multi-plex assay for use in FFPE tumor tissues. Poster Presentation at 24th EORTC NCI AACR Symposium, Abstr 561 December 7, 2012. Dublin, Ireland.
46. Hembrough T, Thyparambil S, Henderson L, Rambo B, Cecchi F, et al. (2014) Quantification of MET expression using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue; San Francisco, CA. January 16-18.
47. Stricker T, Catenacci DV, Seiwert TY (2011) Molecular profiling of cancer - the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 38: 173-185.
48. Khoury J, Catenacci DV (in press) Next-Generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med 2014.
49. Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, et al. (2006) Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 12: 4154-4162.
50. Archidiacono N, Antonacci R, Marzella R, Finelli P, Lonoce A, et al. (1995) Comparative mapping of human alphoid sequences in great apes, using fluorescence in situ hybridization. Genomics 1995 Jan 20; 25(2): 477-84.